Evolus, Inc. EOLS

Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalizatio

David Gill appointed Chair of the Telix Board, effective immediately.Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair. MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chai

As the global neurotoxin market expands across cosmetic facial aesthetics and neurological therapeutic applications, Dysport (abobotulinumtoxinA)—developed and commercialized by Ipsen and Galderma—continues to maintain a critical market share alongside Botox (AbbVie/Allergan), Xeomin (Merz Aesthetics), Jeuveau (Evolus), and long-acting entry Daxxify (Revance Therapeutics).Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The "DYSPORT Sales Forecast and Market Size Analysis - 2034" has been added to Rese

Evolus Inc (EOLS) raises full-year guidance on strong portfolio growth and strategic expansion into skin quality with Profhilo partnership.

NEWPORT BEACH, Calif., August 05, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026.

NEWPORT BEACH, Calif., August 04, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies’ existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme® (pronounced "esteem") collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zeal

Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NEWPORT BEACH, Calif., July 22, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.

NEWPORT BEACH, Calif., July 10, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company’s common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive

NEWPORT BEACH, Calif., July 08, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States.